JP2010526101A - 直接作用型および可逆的ｐ２ｙ１２阻害剤の静脈および経口投与 - Google Patents

直接作用型および可逆的ｐ２ｙ１２阻害剤の静脈および経口投与 Download PDF

Info

Publication number
JP2010526101A
JP2010526101A JP2010506688A JP2010506688A JP2010526101A JP 2010526101 A JP2010526101 A JP 2010526101A JP 2010506688 A JP2010506688 A JP 2010506688A JP 2010506688 A JP2010506688 A JP 2010506688A JP 2010526101 A JP2010526101 A JP 2010526101A
Authority
JP
Japan
Prior art keywords
compound
composition
platelet aggregation
unit dose
inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010506688A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010526101A5 (enExample
Inventor
ロバート・エム・スカーバーロウ
ダニエル・ディ・グレトラー
パメラ・ビー・コンリー
パトリック・アンドレ
アシワト・ハッチャリーラハ
デイビッド・アール・フィリップス
アンジャリ・パンディ
フアン・ウォリン
Original Assignee
ポートラ ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ポートラ ファーマシューティカルズ， インコーポレイテッド filed Critical ポートラ ファーマシューティカルズ， インコーポレイテッド
Publication of JP2010526101A publication Critical patent/JP2010526101A/ja
Publication of JP2010526101A5 publication Critical patent/JP2010526101A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2010506688A 2007-05-02 2008-05-02 直接作用型および可逆的ｐ２ｙ１２阻害剤の静脈および経口投与 Withdrawn JP2010526101A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91564907P 2007-05-02 2007-05-02
US94792107P 2007-07-03 2007-07-03
PCT/US2008/062518 WO2008137753A2 (en) 2007-05-02 2008-05-02 Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor

Publications (2)

Publication Number Publication Date
JP2010526101A true JP2010526101A (ja) 2010-07-29
JP2010526101A5 JP2010526101A5 (enExample) 2011-06-23

Family

ID=39587015

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010506688A Withdrawn JP2010526101A (ja) 2007-05-02 2008-05-02 直接作用型および可逆的ｐ２ｙ１２阻害剤の静脈および経口投与

Country Status (17)

Country Link
US (2) US20090048216A1 (enExample)
EP (1) EP2079464A2 (enExample)
JP (1) JP2010526101A (enExample)
KR (1) KR20100029746A (enExample)
CN (1) CN101795682A (enExample)
AU (1) AU2008247483A1 (enExample)
BR (1) BRPI0811476A2 (enExample)
CA (1) CA2686203A1 (enExample)
CO (1) CO6241104A2 (enExample)
EA (1) EA200901473A1 (enExample)
EC (1) ECSP099778A (enExample)
GT (1) GT200900284A (enExample)
IL (1) IL201834A0 (enExample)
MA (1) MA31663B1 (enExample)
MX (1) MX2009011843A (enExample)
TN (1) TN2009000451A1 (enExample)
WO (1) WO2008137753A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013544271A (ja) * 2010-12-03 2013-12-12 ポートラ ファーマシューティカルズ， インコーポレイテッド 式（ｉ）の化合物の薬学的組成物、投薬形態、および新規の形態、ならびにその使用方法

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2627719C (en) * 2005-11-03 2016-07-12 Portola Pharmaceuticals, Inc. [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto
CN101622234B (zh) * 2007-03-06 2013-08-07 诺瓦提斯公司 适于治疗炎性或变应性病症的二环有机化合物
US20090156620A1 (en) * 2007-05-02 2009-06-18 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto
CA2686221A1 (en) * 2007-05-02 2008-11-13 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto
US9427448B2 (en) * 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
CN102271685A (zh) * 2008-12-30 2011-12-07 斯若姆博洛捷克有限公司 鉴定发展成器官功能衰竭的风险提高的危重患者的方法及用于其治疗的化合物
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
EP2498731B1 (en) 2009-11-11 2020-01-22 Chiesi Farmaceutici S.p.A. Methods of treating or preventing stent thrombosis
ES2550033T3 (es) * 2009-12-23 2015-11-04 Ratiopharm Gmbh Forma de dosificación farmacéutica sólida de ticagrelor
WO2011088152A1 (en) 2010-01-12 2011-07-21 Portola Pharmaceuticals, Inc. Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof
WO2011137459A1 (en) * 2010-04-30 2011-11-03 Portola Pharmaceuticals, Inc. Dosage forms of elinogrel and methods of injectable administration thereof
US9029095B2 (en) 2010-12-01 2015-05-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method and kits for determining platelet susceptibility to activation in a patient
SG11201908128YA (en) 2017-03-15 2019-10-30 Idorsia Pharmaceuticals Ltd Subcutaneous administration of a p2y12 receptor antagonist
ES3067885T3 (en) 2017-06-23 2026-05-26 Chiesi Farm Spa Cangrelor for the treatment and/or prevention of shunt or stent thrombosis
CN107462648B (zh) * 2017-08-21 2019-09-27 盐城锦明药业有限公司 一种Cangrelor中间体腺苷-2-硫酮的高效液相色谱检测方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6906063B2 (en) 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
CA2627719C (en) 2005-11-03 2016-07-12 Portola Pharmaceuticals, Inc. [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013544271A (ja) * 2010-12-03 2013-12-12 ポートラ ファーマシューティカルズ， インコーポレイテッド 式（ｉ）の化合物の薬学的組成物、投薬形態、および新規の形態、ならびにその使用方法
JP2016026231A (ja) * 2010-12-03 2016-02-12 ポートラ ファーマシューティカルズ， インコーポレイテッド 式（ｉ）の化合物の薬学的組成物、投薬形態、および新規の形態、ならびにその使用方法

Also Published As

Publication number Publication date
US20120009172A1 (en) 2012-01-12
CA2686203A1 (en) 2008-11-13
EA200901473A1 (ru) 2010-06-30
KR20100029746A (ko) 2010-03-17
IL201834A0 (en) 2010-06-16
WO2008137753A3 (en) 2009-02-12
EP2079464A2 (en) 2009-07-22
CO6241104A2 (es) 2011-01-20
ECSP099778A (es) 2010-01-29
US20090048216A1 (en) 2009-02-19
BRPI0811476A2 (pt) 2014-11-04
CN101795682A (zh) 2010-08-04
GT200900284A (es) 2012-01-31
WO2008137753A2 (en) 2008-11-13
TN2009000451A1 (en) 2011-03-31
MX2009011843A (es) 2010-04-22
MA31663B1 (fr) 2010-09-01
AU2008247483A1 (en) 2008-11-13

Similar Documents

Publication Publication Date Title
US20120009172A1 (en) Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor
CN109071454B (zh) 磺酰脲和相关化合物及其用途
KR102948713B1 (ko) 설포닐우레아와 관련 화합물 및 그 용도
JP5509406B2 (ja) ［４−（６−ハロ−７−置換−２，４−ジオキソ−１，４−ジヒドロ−２ｈ−キナゾリン−３−イル）−フェニル］−５−クロロ−チオフェン−２−イル−スルホニル尿素、ならびにそれに関連する形態および方法
JP6820282B2 (ja) スルホンアミド誘導体及びそれを含有する医薬組成物
TW200307667A (en) Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
JP2022511555A (ja) 非ＡＴＰ／触媒部位ｐ３８マイトジェン活性化プロテインキナーゼ阻害剤
MX2007014114A (es) Derivados de piridona para modular el sistema de proteina cinasa activada por estres.
JP2009544602A (ja) サイクリン依存性キナーゼ阻害剤の医学的使用
JP2022046803A (ja) 内皮安定化及び抗炎症活性を有する非触媒基質選択的ｐ３８α特異的ＭＡＰＫ阻害剤、及びその使用方法
JP2023085345A (ja) グリコシド化合物の誘導体からなる血管新生促進薬物を含有する予防薬
TW201710248A (zh) 做為ｎｒ２ｂ ｎｍｄａ受體拮抗劑之３，３－二氟哌啶胺基甲酸酯雜環化合物
JPWO2019189555A1 (ja) 複素環化合物
CN101720324A (zh) [4-(6-氟-7-甲基氨基-2,4-二氧代-1,4-二氢-2h-喹唑啉-3-基)-苯基]-5-氯-噻吩-2-基-磺酰基脲盐、其相关的形式和方法
EP4053108B1 (en) Compound containing benzene ring and application thereof
US12285436B2 (en) Substituted pyridines as DNMT1 inhibitors
KR20110093843A (ko) 〔4-(6-플루오로-7-메틸아미노-2,4-디옥소-1,4-디히드로-2ｈ-퀴나졸린-3-일)-페닐〕-5-클로로-티오펜-2-일-술포닐우레아 염, 그에 관련된 형태 및 방법
WO2022225909A1 (en) Small-molecule inhibitors for beta-catenin/bcell lymphoma 9 protein-protein interaction
JP2021522290A (ja) １−イミダゾチアジアゾロ−２ｈ−ピロール−５−オン誘導体
JP2019196308A (ja) 複素環アミド化合物
TW201738221A (zh) 新的喜巴辛類似物、其藥物組合物及其在醫藥中的應用
RU2526624C2 (ru) Производное сложного эфира тиенопиридина, содержащее цианогруппу, способ его получения, его применение и композиция на его основе
RU2795512C2 (ru) Сульфонилмочевины и родственные соединения и их применение
HK40060133B (en) Non-atp/catalytic site p38 mitogen activated protein kinase inhibitors
KR20070107156A (ko) 공지된 피롤리딘 Ｘａ 인자 억제제의 결정질 형태

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110502

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110502

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20120831